Gsk (GSK) Common Equity (2009 - 2026)

Gsk (GSK) has 11 years of Common Equity data on file, last reported at $21.8 billion in Q4 2025.

• In Q4 2025, Common Equity rose 24.15% year-over-year to $21.8 billion; the TTM figure through Dec 2025 stood at $21.8 billion (up 24.15% YoY), while the FY2025 annual figure was $21.8 billion, up 24.15% from the prior year.
• Common Equity grew to $21.8 billion in Q4 2025, from $17.5 billion in the prior quarter.
• Across five years, Common Equity topped out at $21.8 billion in Q4 2025 and bottomed at $12.4 billion in Q4 2022.
• A 5-year average of $17.7 billion and a median of $17.5 billion in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity plunged 38.75% — and 2023, when it jumped 33.26%.
• Year by year, Common Equity stood at $20.3 billion in 2021, then plunged by 38.75% to $12.4 billion in 2022, then jumped by 33.26% to $16.6 billion in 2023, then increased by 5.92% to $17.5 billion in 2024, then grew by 24.15% to $21.8 billion in 2025.
• The last three Common Equity figures came in at $21.8 billion (Q4 2025), $17.5 billion (Q4 2024), and $16.6 billion (Q4 2023), per Business Quant data.

Peer Comparison